OK Biotech Co., Ltd. (4155.TW)
TWD 20.9
(-0.71%)
TWD 20.9
(-0.71%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 94.1 Million TWD | -75.63% |
| 2022 | 386.14 Million TWD | -3.89% |
| 2021 | 401.76 Million TWD | 214.69% |
| 2020 | 127.67 Million TWD | -55.74% |
| 2019 | 288.44 Million TWD | 12.79% |
| 2018 | 255.74 Million TWD | 30.9% |
| 2017 | 195.36 Million TWD | -15.79% |
| 2016 | 232 Million TWD | -6.85% |
| 2015 | 249.05 Million TWD | 17.98% |
| 2014 | 211.1 Million TWD | -7.12% |
| 2013 | 227.28 Million TWD | 398.43% |
| 2012 | 45.6 Million TWD | 1.33% |
| 2011 | 45 Million TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 92.43 Million TWD | -2.64% |
| 2024 Q2 | 210.28 Million TWD | 134.94% |
| 2023 Q4 | 94.1 Million TWD | -2.78% |
| 2023 Q2 | 151.53 Million TWD | -10.67% |
| 2023 Q3 | 96.79 Million TWD | -36.12% |
| 2023 FY | 94.1 Million TWD | -75.63% |
| 2023 Q1 | 169.63 Million TWD | -56.07% |
| 2022 Q4 | 386.14 Million TWD | -0.36% |
| 2022 FY | 386.14 Million TWD | -3.89% |
| 2022 Q1 | 403.6 Million TWD | 0.46% |
| 2022 Q2 | 401.69 Million TWD | -0.47% |
| 2022 Q3 | 387.54 Million TWD | -3.52% |
| 2021 Q3 | 408.57 Million TWD | -0.6% |
| 2021 Q4 | 401.76 Million TWD | -1.67% |
| 2021 FY | 401.76 Million TWD | 214.69% |
| 2021 Q1 | 123.2 Million TWD | -3.5% |
| 2021 Q2 | 411.03 Million TWD | 233.61% |
| 2020 Q3 | 260.75 Million TWD | -0.87% |
| 2020 Q2 | 263.03 Million TWD | -0.03% |
| 2020 Q4 | 127.67 Million TWD | -51.04% |
| 2020 Q1 | 263.11 Million TWD | -8.78% |
| 2020 FY | 127.67 Million TWD | -55.74% |
| 2019 Q3 | 379.63 Million TWD | 50.42% |
| 2019 Q4 | 288.44 Million TWD | -24.02% |
| 2019 Q1 | 258.8 Million TWD | 1.2% |
| 2019 Q2 | 252.37 Million TWD | -2.48% |
| 2019 FY | 288.44 Million TWD | 12.79% |
| 2018 Q2 | 151.43 Million TWD | -20.76% |
| 2018 FY | 255.74 Million TWD | 30.9% |
| 2018 Q1 | 191.1 Million TWD | -2.18% |
| 2018 Q4 | 255.74 Million TWD | -1.87% |
| 2018 Q3 | 260.61 Million TWD | 72.1% |
| 2017 FY | 195.36 Million TWD | -15.79% |
| 2017 Q4 | 195.36 Million TWD | -2.13% |
| 2017 Q3 | 199.63 Million TWD | -22.89% |
| 2017 Q2 | 258.89 Million TWD | 11.94% |
| 2017 Q1 | 231.28 Million TWD | -0.31% |
| 2016 Q4 | 232 Million TWD | 0.0% |
| 2016 Q1 | - TWD | -100.0% |
| 2016 FY | 232 Million TWD | -6.85% |
| 2016 Q2 | 240.53 Million TWD | 0.0% |
| 2015 Q1 | 203.44 Million TWD | -3.63% |
| 2015 Q3 | 249.05 Million TWD | 22.42% |
| 2015 Q2 | 203.44 Million TWD | 0.0% |
| 2015 FY | 249.05 Million TWD | 17.98% |
| 2015 Q4 | 249.05 Million TWD | 0.0% |
| 2014 Q1 | 219.62 Million TWD | -3.37% |
| 2014 FY | 211.1 Million TWD | -7.12% |
| 2014 Q4 | 211.1 Million TWD | 0.0% |
| 2014 Q3 | 211.1 Million TWD | -3.88% |
| 2014 Q2 | 219.62 Million TWD | 0.0% |
| 2013 Q1 | 234.06 Million TWD | 413.31% |
| 2013 Q2 | 234.06 Million TWD | 0.0% |
| 2013 FY | 227.28 Million TWD | 398.43% |
| 2013 Q4 | 227.28 Million TWD | 0.0% |
| 2013 Q3 | 227.28 Million TWD | -2.9% |
| 2012 Q4 | 45.6 Million TWD | 0.0% |
| 2012 Q2 | 62.1 Million TWD | 0.0% |
| 2012 Q3 | 45.6 Million TWD | -26.57% |
| 2012 FY | 45.6 Million TWD | 1.33% |
| 2011 FY | 45 Million TWD | 0.0% |
| 2011 Q2 | - TWD | 0.0% |
| 2011 Q4 | 45 Million TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 236.82 Million TWD | 60.264% |
| Apex Medical Corp. | 141.16 Million TWD | 33.336% |
| Applied BioCode Corporation | 18.07 Million TWD | -420.561% |